SciBX: Science-Business eXchange Contents: October 18 2012, Volume 5 / Issue 41

TABLE OF CONTENTS October 25 2012, Volume 5 / Issue 42 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Dermatology Endocrine/metabolic disease Hematology Infectious disease Musculoskeletal disease Neurology The Distillery: Techniques Assays and screens Disease models Drug platforms Markers New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Melanoma's hidden act Kai-Jye Lou doi:10.1038/scibx.2012.1100 German researchers have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens. The group now is trying to circumvent this resistance mechanism and thinks doing so could improve treatment responses for T cell therapy protocols. Full Text | PDF Translational Notes Top China's new mAb institute Tim Fulmer doi:10.1038/scibx.2012.1101 The launch of the Shanghai Institute for Advanced Immunochemical Studies marks China's first attempt to establish a center of antibody research on par with research centers in the U.S. and Europe. SIIS will identify targets and develop antibodies to treat cancer as well as infectious, autoimmune and metabolic diseases. Full Text | PDF Targets and Mechanisms Top Myelination from neural stem cells Lauren Martz doi:10.1038/scibx.2012.1102 UCSF, Oregon Health & Science University and StemCells researchers have shown that neural stem cell transplants can remyelinate axons and treat myelination disorders including Pelizaeus-Merzbacher disease. The biotech is planning a Phase II study of neural stem cell transplantation in the indication. Full Text | PDF Tools Top Breg-ging rights Lev Osherovich doi:10.1038/scibx.2012.1103 A Duke University team has figured out how to grow large numbers of regulatory B cells. The researchers used the bounty of cells to tone down autoimmunity in a mouse model of MS. Full Text | PDF Distillery: Therapeutics Cancer Top Mdm2 p53 binding protein homolog (MDM2; HDM2); p53 doi:10.1038/scibx.2012.1104 SAR studies identified a series of MDM2-p53 interaction inhibitors that could be useful for treating cancer. Full Text | PDF Pyruvate kinase M2 isozyme (PKM2) doi:10.1038/scibx.2012.1105 In vitro and cell culture studies suggest PKM2 activators could help treat cancers with low tumor serine levels. Full Text | PDF BCR-ABL tyrosine kinase doi:10.1038/scibx.2012.1106 Cell culture studies suggest Bosulif bosutinib plus danusertib could help treat CML resistant to Gleevec imatinib. Full Text | PDF MAP kinase kinase kinase 8 (MAP3K8; COT; TPL2); c-Met proto-oncogene (MET; HGFR); hepatocyte growth factor/scatter factor (HGF/SF) doi:10.1038/scibx.2012.1107 Mouse studies suggest increasing TPL2 signaling could help prevent colitis-associated cancer. Full Text | PDF Anaplastic lymphoma kinase (ALK); nucleophosmin (NPM1; B23); platelet derived growth factor receptor A (PDGFRA; PDGFR2; CD140A); PDGFRB (PDGFR1; CD140B) doi:10.1038/scibx.2012.1108 Studies in mice and in a single patient suggest inhibiting PDGFR2 could help treat anaplastic large cell lymphomas driven by the NPM1-ALK oncoprotein. Full Text | PDF Dermatology Top Leukotriene B4 (LTB4); leukotriene A4 hydrolase (LTA4H); doi:10.1038/scibx.2012.1109 Mouse studies suggest inhibiting LTB4 could help treat atopic dermatitis. Full Text | PDF MAS-related GPR member D (MRGPRD) doi:10.1038/scibx.2012.1110 Human and mouse studies suggest blocking activation of MRGPRD could help treat histamine-independent itch. Full Text | PDF Endocrine/metabolic disease Top X-box binding protein 1 (XBP1); endoplasmic reticulum to nucleus signaling 1 (ERN1; IRE1) doi:10.1038/scibx.2012.1111 Studies in mice suggest antagonizing XBP1 or IRE1 could help treat dyslipidemia. Full Text | PDF Unknown doi:10.1038/scibx.2012.1112 Cell culture studies suggest compounds that improve lysosomal exocytosis could help treat lysosomal storage disorders such as Niemann-Pick type C disease and Wolman disease. Full Text | PDF Hematology Top Factor IX doi:10.1038/scibx.2012.1113 Mouse studies suggest lentivirus-mediated delivery of a hyperfunctional mutant factor IX could help treat hemophilia. Full Text | PDF Infectious disease Top Chemokine CXC motif ligand 9 (CXCL9; MIG); CXCL10 (IP-10) doi:10.1038/scibx.2012.1114 Mouse studies suggest a prime-pull vaccination strategy could help prevent HSV-2 infection. Full Text | PDF Neuraminidase (NEU1; SIAL1) doi:10.1038/scibx.2012.1115 In vitro and mouse studies identified oseltamivir phosphonate derivatives that could help treat drug-resistant influenza. Full Text | PDF Musculoskeletal disease Top Survival of motor neuron 1 telomeric (SMN1); survival of motor neuron 2 centromeric (SMN2); stasimon (STAS; CG8408) doi:10.1038/scibx.2012.1116 Fruit fly and zebrafish studies suggest restoring SMN levels in specific neuronal subpopulations and promoting expression of the downstream protein STAS could help treat SMA. Full Text | PDF Neurology Top γ-Secretase; β-amyloid 42 doi:10.1038/scibx.2012.1117 In vitro and mouse studies identified metabolically stable γ-secretase modulators that could help treat familial AD. Full Text | PDF Ribosomal protein S6 kinase 70 kDa polypeptide 1 (RPS6KB1; S6K1); fragile X mental retardation 1 (FMR1) doi:10.1038/scibx.2012.1118 Mouse studies suggest inhibiting S6K1 could help treat fragile X syndrome. Full Text | PDF Huntingtin (HTT) doi:10.1038/scibx.2012.1119 Cell culture and mouse studies suggest zinc finger proteins (ZFPs) could help treat HD. Full Text | PDF Proteolipid protein 1 (PLP1) doi:10.1038/scibx.2012.1120 Mouse and patient studies suggest human neural stem cells could help treat hypomyelination diseases. Full Text | PDF Distillery: Techniques Assays and screens Top Multiplex screening for interacting compounds (MuSIC) to help identify drug combinations to treat HIV/AIDS doi:10.1038/scibx.2012.1121 MuSIC could be used to help identify drug combinations to treat HIV infection. Full Text | PDF Disease models Top Model for T cell therapy resistance in melanoma doi:10.1038/scibx.2012.1122 A mouse model for T cell resistance suggests T cell–based melanoma therapies should target both melanocytic and nonmelanocytic antigens to help prevent disease relapse. Full Text | PDF Drug platforms Top Autologous regulatory B (Breg) cell therapy for autoimmune diseases doi:10.1038/scibx.2012.1123 Cell culture and mouse studies suggest Breg cells cultured ex vivo could be useful for treating autoimmune diseases. Full Text | PDF Expansion of embryonic stem cell (ESC)-derived progenitors in organ-matched mesenchymal cultures doi:10.1038/scibx.2012.1124 Expansion of ESC-derived progenitors in organ-matched mesenchymal cell culture could be used to generate adequate cell numbers for cell-based therapies. Full Text | PDF Markers Top DNA methylation signatures in chronic lymphocytic leukemia (CLL) doi:10.1038/scibx.2012.1125 DNA methylation signatures could help identify CLL subtypes and improve disease prognosis. Full Text | PDF Soluble APP770 as an early marker of acute coronary syndrome (ACS) doi:10.1038/scibx.2012.1126 Cell culture, human sample and rodent studies suggest serum APP770 levels could help diagnose ACS. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.